title: Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
abstract: We recently showed that increased urinary excretion of the cross-linked, nonisomerized form of the C-telopeptide of collagen type I (alphaalphaCTX) could be a sensitive indicator of the presence of bone metastases in breast cancer patients. The present study was sought to investigate (a) the localization of alphaCTX epitopes in the proximity of a bone metastasis and (b) the relationship between number of metastases and the urinary excretion of alphaalphaCTX. Adjacent bone sections from breast cancer patients were stained for the presence of tumor cells (anti-cytokeratin antibody), osteoclasts (TRAcP activity), and alphaCTX (anti-alphaCTX antibody). The association between the extent of metastatic bone disease and urinary excretion of alphaalphaCTX measured with ELISA was assessed in 90 breast cancer patients (45 with bone metastasis and 45 without bone metastasis). Immunohistochemistry revealed accumulation of TRAcP-positive osteoclasts and intense staining for alphaCTX epitopes in the proximity of cytokeratin-positive bone metastasis. Areas of alphaCTX staining showed unstructured bone tissue under polarized light. In addition, there was a significant linear association between the number of bone metastases and the urinary levels of alphaalphaCTX in breast cancer patients with metastatic bone disease, independent of age and body mass index (r = 0.56, P < 0.001). The estimated relative increases in alphaalphaCTX associated with the presence of one, two, or three metastases are 38%, 57%, and 81%, respectively. Taken into account the 17% intraindividual variation of the assay, alphaalphaCTX could be a sensitive biochemical marker for the close monitoring of cancer patients aiming the facilitation of early metastasis detection.
authors.affiliation: Nordic Bioscience A/S, Herlev, Denmark. djl@nordicbioscience.com
authors.forename: Diana J
authors.initials: DJ
authors.lastname: Leeming
authors.forename: Günter
authors.initials: G
authors.lastname: Delling
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Koizumi
authors.forename: Kim
authors.initials: K
authors.lastname: Henriksen
authors.forename: Morten A
authors.initials: MA
authors.lastname: Karsdal
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Per
authors.initials: P
authors.lastname: Qvist
authors.forename: László B
authors.initials: LB
authors.lastname: Tankó
authors.forename: Inger
authors.initials: I
authors.lastname: Byrjalsen
mesh_terms: D014408:Biomarkers, Tumor / Q000652:urine*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary / Q000652:urine; D001943:Breast Neoplasms / Q000473:pathology* / Q000652:urine; D024042:Collagen Type I / Q000652:urine*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D009361:Neoplasm Invasiveness / Q000175:diagnosis*; D010010:Osteoclasts / Q000378:metabolism; D010455:Peptides / Q000652:urine*
chemical_list: D014408:Biomarkers, Tumor; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide